Background
Results
Expression of MAGL is upregulated in HCC patients and associated with recurrence
MAGL overexpression predicts a poor clinical outcome of HCC
MAGL staining | |||
---|---|---|---|
Variables | Low (n = 77) n(%) | High (n = 93) n(%) |
P
|
Gender | |||
Male | 67 (87.0) | 78 (83.9) | 0.565 |
Female | 10 (13.0) | 15 (16.1) | |
Age(years) | |||
≤50 | 28 (36.4) | 37 (39.8) | 0.648 |
>50 | 49 (63.6) | 56 (60.2) | |
HBsAg | |||
Negative | 14 (18.2) | 11 (11.8) | 0.244 |
Positive | 63 (81.8) | 82 (88.2) | |
HCV | |||
Negative | 74 (96.1) | 91 (97.8) | 0.659 |
Positive | 3 (3.9) | 2 (2.2) | |
Liver cirrhosis | |||
No | 30 (39.0) | 29 (31.2) | 0.289 |
Yes | 47 (61.0) | 64 (68.8) | |
AFP(ng/ml) | |||
≤20 | 28 (36.4) | 23 (24.7) | 0.099 |
>20 | 49 (63.6) | 70 (75.3) | |
Tumor number | |||
Single | 56 (72.7) | 55 (59.1) | 0.064 |
Multiple | 21 (27.3) | 38 (40.9) | |
Tumor size(cm) | |||
≤5 | 44 (57.1) | 39 (41.9) |
0.048
|
>5 | 33 (42.9) | 54 (58.1) | |
Tumor encapsulation | |||
Complete | 37 (48.1) | 49 (52.7) | 0.547 |
Incomplete | 40 (51.9) | 44 (47.3) | |
Microvascular invasion | |||
Absent | 48 (62.3) | 42 (45.2) |
0.026
|
Present | 29 (37.7) | 51 (54.8) | |
Edmondson grade | |||
I–II | 16 (20.8) | 36 (38.7) |
0.012
|
III–IV | 61 (79.2) | 57 (61.3) | |
TNM stage | |||
I | 18 (23.4) | 5 (5.4) |
0.001
|
II–III | 59 (76.6) | 88 (94.6) |
OS | TTR | |||
---|---|---|---|---|
Variablesa
| HR (95% CI) |
P
| HR (95% CI) |
P
|
Gender (male vs. female) | 1.375 (0.751–2.518) | 0.302 | 1.072 (0.605–1.898) | 0.811 |
Age (≤50 vs. >50 years) | 0.863 (0.577–1.289) | 0.471 | 1.140 (0.748–1.738) | 0.542 |
HBsAg (negative vs. positive) | 1.444 (0.788–2.646) | 0.234 | 1.833 (0.974–3.449) |
0.061
|
HCV (negative vs. positive) | 1.157 (0.365–3.669) | 0.805 | 0.612 (0.150–2.503) | 0.494 |
Liver cirrhosis (no vs. yes) | 1.337 (0.865–2.067) |
0.192
| 1.476 (0.947–2.299) |
0.085
|
AFP (≤20 vs. >20 ng/ml) | 1.408 (0.893–2.219) |
0.140
| 1.005 (0.650–1.553) | 0.983 |
Tumor number (single vs. multiple) | 1.731 (1.160–2.581) |
0.007
| 1.877 (1.247–2.826) |
0.003
|
Tumor size (≤5 vs. >5 cm) | 2.211 (1.461–3.345) |
<0.001
| 1.936 (1.278–2.934) |
0.002
|
Tumor encapsulation (complete vs. incomplete) | 1.566 (1.049–2.338) |
0.028
| 1.116 (0.744–1.676) | 0.595 |
Microvascular invasion (absent vs. present) | 1.602 (1.074–2.389) |
0.021
| 1.556 (1.033–2.345) |
0.035
|
Edmondson grade (I–II vs. III–IV) | 1.401 (0.898–2.184) |
0.137
| 1.282 (0.826–1.990) | 0.268 |
TNM stage (I vs. II–III) | 2.117 (1.026–4.369) |
0.042
| 3.260 (1.423–7.468) |
0.005
|
MAGL (low vs. high) | 1.856 (1.220–2.823) |
0.004
| 2.040 (1.331–3.128) |
0.001
|
OS | TTR | |||
---|---|---|---|---|
Variablesa
| HR (95% CI) |
P
| HR (95% CI) |
P
|
HBsAg (negative vs. positive) | NA | 1.342 (0.700–2.573) | 0.377 | |
Liver cirrhosis (no vs. yes) | 1.278 (0.795–2.053) | 0.311 | 1.356 (0.855–2.149) | 0.195 |
AFP (≤20 vs. >20 ng/ml) | 1.487 (0.915–2.418) | 0.110 | NA | |
Tumor number (single vs. multiple) | 1.642 (1.063–2.534) |
0.025
| 1.671 (1.082–2.582) |
0.021
|
Tumor size (≤5 vs. >5 cm) | 2.712 (1.447–5.083) |
0.002
| 1.874 (1.009–3.481) |
0.047
|
Tumor encapsulation (complete vs. incomplete) | 1.504 (0.988–2.289) | 0.057 | NA | |
Microvascular invasion (absent vs. present) | 0.711 (0.385–1.315) | 0.277 | 0.775 (0.419–1.436) | 0.418 |
Edmondson grade (I–II vs. III–IV) | 1.574 (0.989–2.504) | 0.056 | NA | |
TNM stage (I vs. II–III) | 1.023 (0.444–2.358) | 0.957 | 1.726 (0.687–4.340) | 0.246 |
MAGL (low vs. high) | 1.628 (1.020–2.597) |
0.041
| 1.593 (1.011–2.510) |
0.045
|